Progesterone Market Size, Share Global Analysis Report, 2022 – 2030

Industry Insights

[225+ Pages Report]  According to the report published by Facts and Factors, the global progesterone market size was worth around USD 1027 million in 2021 and is predicted to grow to around USD 2136 million by 2030 with a compound annual growth rate (CAGR) of roughly 13 % between 2022 and 2030. The report analyzes the global progesterone market drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the progesterone market.

Market Overview

Progesterone is a steroid classified in the endogenous category. It is a progesterone sex hormone that is used to treat medical concerns like pregnancy, menstrual cycle, and embryogenesis in the female population of humans or other species. It falls under the category of progestogens. It is found in the human body as a progestogen. Progesterone has different types of crucial functions in the body while also being an essential metabolic intermediate used to produce other forms of endogenous steroids including corticosteroids and sex hormones. It plays the role of a neurosteroid responsible for brain functions. In the presence of estrogen, progesterone has a variety of physiological impacts on the body.

In such situations, estrogen with the help of estrogen receptors is responsible for regulating progesterone expression. For instance, in breast tissue, estrogen encourages progesterone to help in the development of lobuloalveolar. They also play a critical role in the reproduction process as it is sometimes referred to as the hormone of pregnancy owing to the many roles it has to play in the development of the fetus. In sexual terms, there seems to be a connection between female libido and the neurosteroid active metabolite allopregnanolone of progesterone.

Key Insights

• As per the analysis shared by our research analyst, the global progesterone market is estimated to grow annually at a CAGR of around 13% over the forecast period (2022-2030)
• In terms of revenue, the global progesterone market size was valued at around USD 1027 million in 2021 and is projected to reach USD 2136 million, by 2030.
• The market is projected to grow at a significant rate due to the growing cases of AIDS, breast cancer, and amenorrhea
• Based on mode of delivery segmentation, oral was predicted to show maximum market share in the year 2021
• Based on application segmentation, regulation of the menstrual cycle was the leading application in 2021
• On the basis of region, North America was the leading revenue generator in 2021

Growth Drivers

• Growing number of cases related to AIDS, breast cancer, and amenorrhea to propel market demand

The global progesterone market is projected to grow owing to the growing number of cases related to breast cancer, AIDS, and amenorrhea across the globe and the use of progesterone in treating these medical issues. Several studies have concluded that progesterone along with estradiol can help to regulate several medical conditions including the ones associated with human immunodeficiency virus (HIV). During the treatment, progesterone and estradiol not only interact with the immune system but also act directly on the virus thus helping the body to fight the impact of the infection.

However, the final effect of these steroids will depend on the HIV infection phase but generally speaking, they have proven to create a protective shield against the virus. As per the official reports of the World Health Organization, as of 2021, there are over 38.4 million who are HIV-infected. In breast cancer treatment, hormone therapy is only restricted to cases that have shown the existence of receptors for naturally occurring hormones like progesterone and estrogen.

Restraints

• Side effects associated with progesterone treatment to restrict market expansion

The global market could face growth limitations owing to the recorded presence of side effects after the application of progesterone treatment. Some of the most common side effects are fluctuations in weight like weight gain or weight loss, increased quantity of facial and body hair, headache, constant breast tenderness, and loss of scalp hair. Although the conditions may not seem serious, these can take serious turns if the progesterone treatment is not conducted under a controlled and well-informed environment.

Opportunities

• Increasing research & development activities to provide growth opportunities

The global market is projected to register more growth opportunities owing to the increase in investment and the number of research & development (R&D) activities conducted by private research institutes as well as government bodies to find out more applications of hormone therapy. There are various ongoing research studies to analyze the effect of progesterone in postmenopausal and perimenopausal women. Many scientific communities are also interested in understanding the influencing factors like the progestin structure and their binding equation with the progesterone receptors.

Challenges

• Lack of awareness to act as a major challenge during the forecast period

The global market players may face challenges owing to the lack of awareness regarding hormone therapy amongst the population as well as the medical community. The underdeveloped nations lack the necessary infrastructure responsible for providing quality education and training. The lack of awareness also exists amongst the patient population due to various factors like inaccessibility to information and poor government programs to educate the population to name a few. Medical professionals also face issues in dealing with wrong information or knowledge that people have about hormone therapy.

Segmentation Analysis

The global progesterone market is segmented based on application, type, mode of delivery, and region

Based on application, the global market divisions are dysfunctional uterine bleeding, regulation of the menstrual cycle, contraception, hyperplastic precursor lesions, and endometrial cancer. In 2021, the global market registered the highest applications of the steroid in the regulation of the menstrual cycle segment due to the growing number of women population that face irregularities in their menstrual cycle which is the main reason for different intensities of menstrual blood flow, missed or delayed menstrual cycle dates.

Various menstrual hormonal problems like polycystic ovary syndrome (PCOS) or polycystic ovarian disease (PCOD) have been on the rise in the last few years and more cases are being registered due to growing awareness. As per official records, 1 in every 10 Australian women suffer from PCOS.

Based on the mode of delivery, the global market divisions are oral, injectable, and suspended form. The oral segment led the global market expansion in 2021, followed by the injectable form. Most progesterone-related drugs taken by women are available in oral form as there is less discomfort however some medications can also be administered using injections or through the women's sex organ. Progesterone treatment amongst pregnant women helps prevent premature birth and is recommended to start before or up to 24 months of pregnancy.

Recent Developments:

• In December 2019, Mankind Pharma, a leading drug developer, launched Dydrogesterone tablets in the Indian market. The medicine is recorded to help treat infertility problems along with complications during pregnancy. With this launch, the company has become the second in the world to develop such a drug
• In September 2022, Gyane Pill was set to become of the top-selling drugs in India and become one of the first gynecology therapies to achieve the status

Report Scope

Regional Analysis

• North America to generate the highest revenue by 2030

The global progesterone market is projected to witness the highest growth in North America with the US leading the regional market. The growth is anticipated to be driven by the growing number of US Food and Drugs Administration approval for progesterone-related medicines and treatment. The ongoing research to understand and further develop hormonal therapy could act as a pushing factor during the growth period. In 2011, March of Dimes became the first US FDA-approved drug to be used for the prevention of preterm births.

The medicine is administered in women who have given birth to a premature child to prevent the same in case of the second childbirth. The regional market is projected to be further propelled by the growing investments in the pharmaceutical sector. For instance, between 2009 and 2019, the US spending on the pharmaceutical industry increased from USD 253 billion to USD 345 billion, as quoted by the Institute of New Economic Thinking.

Competitive Analysis

• Cadila Pharmaceuticals 
• ALKEM Labs 
• Cipla Ltd 
• Teva Pharmaceuticals 
• BioNPharma

The global progesterone market is segmented as follows:

By Application Segment Analysis

• Dysfunctional Uterine Bleeding
• Regulation Of The Menstrual Cycle
• Contraception
• Hyperplastic Precursor Lesions
• Endometrial Cancer

By Type Segment Analysis

• Synthetic
• Natural

By Mode of Delivery Segment Analysis

• Oral
• Injectable
• Suspended Form

By Regional Segment Analysis

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Nordic Countries
    • Denmark
    • Sweden
    • Norway
  • Benelux Union
    • Belgium
    • The Netherlands
    • Luxembourg
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Southeast Asia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Rest of Southeast Asia
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America